Healthcare entity
All 1 tracked stories fall under one category: medical-devices. Of the tracked stories, 1 of 1 also mention Charles Schwab, the most common co-covered peer. Each story carries 2 original sources on average, compared with 3.3 for the broader beat in this window.
Last mentioned: Mar 25, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: medical-devices. Of the tracked stories, 1 of 1 also mention Charles Schwab, the most common co-covered peer. Each story carries 2 original sources on average, compared with 3.3 for the broader beat in this window. Their average consequence score of 7 runs above the beat's 6.6 for that window. We currently track 1 Healthcare story that mention Maher Masoud, all published on March 25, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 26 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Maher Masoud. Shared-story counts are live from our verified record — not editorial picks.
MaxCyte reported a 15% revenue decline for 2025, driven by the loss of six clinical programs and reduced spending from its largest customer. Despite these headwinds, the company expanded its installed base to 857 units and significantly improved gross margins through aggressive cost-cutting measures.
Source: Motley Fool Transcribing (us) · Motley Fool Transcribing (us)
Maher Masoud is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
